Comparing Rigel Pharmaceuticals (NASDAQ:RIGL) & Champions Oncology (NASDAQ:CSBR)

Rigel Pharmaceuticals (NASDAQ:RIGL) and Champions Oncology (NASDAQ:CSBR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability and risk.

Earnings and Valuation

This table compares Rigel Pharmaceuticals and Champions Oncology”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28 million	2.02	$367.02 million	$18.72	1.71
Champions Oncology	$57.95 million	1.54	$4.70 million	($0.16)	-40.13

Rigel Pharmaceuticals has higher revenue and earnings than Champions Oncology. Champions Oncology is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Rigel Pharmaceuticals and Champions Oncology, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	1	2	3	0	2.33
Champions Oncology	1	0	0	0	1.00

Rigel Pharmaceuticals currently has a consensus price target of $54.50, indicating a potential upside of 69.89%. Given Rigel Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Rigel Pharmaceuticals is more favorable than Champions Oncology.

Institutional and Insider Ownership

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 41.3% of Champions Oncology shares are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Comparatively, 47.0% of Champions Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Rigel Pharmaceuticals and Champions Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	121.50%	47.99%	32.40%
Champions Oncology	-3.94%	-57.31%	-7.51%

Risk and Volatility

Rigel Pharmaceuticals has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Champions Oncology has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500.

Summary

Rigel Pharmaceuticals beats Champions Oncology on 13 of the 14 factors compared between the two stocks.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

About Champions Oncology

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.